DHT(Dihydrotestosterone) ELISA Kit (E-EL-0031)

This ELISA kit uses the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with Universal DHT. During the reaction, Universal DHT in the sample or standard competes with a fixed amount of Universal DHT on the solid phase supporter for sites on the Biotinylated Detection Ab specific to Universal DHT. Excess conjugate and unbound sample or standard are washed away, and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well and incubated. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns from blue to yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Universal DHT in tested samples can be calculated by comparing the OD of the samples to the standard curve.

Dihydrotestosterone (DHT) is a potent androgen produced from testosterone by the enzyme 5alpha-reductase. It binds the androgen receptor with considerably higher affinity than testosterone and mediates androgen action locally in tissues with high 5alpha-reductase expression, notably the prostate, skin and scalp hair follicles; two isoenzymes, SRD5A1 and SRD5A2, catalyze this conversion in peripheral tissues. Its actions resemble those of testosterone but are more potent, and because it is not aromatized to estrogen its effects are purely androgenic. Through the ligand-bound androgen receptor it regulates transcription of androgen-responsive genes, supporting male secondary sexual characteristics, external genital maturation, and prostate growth and function. Accumulation in scalp tissue drives androgenetic alopecia, and circulating DHT participates in the negative feedback control of the hypothalamic-pituitary-gonadal axis. Measurement of DHT is important for assessing androgen status and for discriminating disorders of androgen metabolism, including 5alpha-reductase deficiency. Altered levels are associated with benign prostatic hyperplasia, prostate cancer, androgenetic alopecia and polycystic ovary syndrome. Quantitation in serum, plasma or tissue homogenates allows monitoring of 5alpha-reductase inhibitor therapy and supports reproductive endocrine research.